Peptide Research Week in Review: 26 August-1 September 2026

What Happened in Peptide Research This Week (26 Aug-1 Sep 2026)?

Five separate items published across the week, each measuring the gap between how a compound is actually used and what the evidence underneath it actually shows. A cohort study found gray-market retatrutide users losing roughly half the weight seen in matched trial participants, with more cardiovascular and neuropsychiatric symptoms besides.[1] A sports-medicine literature audit found exactly one injectable peptide class — licensed GLP-1 receptor agonists — with reproducible randomised evidence, and everything else researchers are using still investigational.[2] A mechanistic MOTS-c study in mice reported real mitochondrial effects with no exogenous dosing in its human arm.[3] A 113-study NAD+ review found no published trial of intravenous or intramuscular NAD+ for anti-ageing outcomes exists at all.[4] And, in the week's one genuinely reassuring finding, a large safety study found licensed GLP-1 drugs carried no elevated risk in people with opioid use disorder.[5]

None of these is a single dramatic headline. Read together, they form a consistent picture: the evidence base for peptide research is being built carefully and slowly, one narrow, well-defined study at a time — while consumer use of several of the same compounds is running well ahead of it.

What Did the Gray-Market Retatrutide Outcomes Study Find?

The gap is not a minor rounding difference — it is roughly half the efficacy, alongside more reported harm. The authors link this to what Eli Lilly's own August lawsuits against six black-market sellers already documented: seized product testing that found doses ranging from zero active ingredient to overdose levels, and in some vials, the wrong drug entirely.[6] An observational, non-randomised comparison, not a trial, but a large one, and it is hard to square with any claim that unregulated supply behaves like the licensed pathway it is copying.

Which Injectable Peptides Actually Have Trial Evidence in Sports Medicine?

This is a peer-reviewed literature audit, not a new dataset — it tells us what already exists, not what will exist next. It lands three weeks after the FDA's Pharmacy Compounding Advisory Committee recommended BPC-157 and TB-500 for the 503A Bulks List,[7] a useful reminder that a compounding recommendation reflects a bulk-substance review process, not new clinical-trial evidence for the compound itself.

What Did the New MOTS-c Mitochondrial Study Show?

The mechanism data is animal-only; the human component measured naturally occurring MOTS-c during exercise rather than testing an administered dose. It sits alongside, and is distinct from, Hudson Biotech's ongoing Phase 2a clinical trial of exogenous MOTS-c, which remains the compound's only human efficacy study to date.[8]

What Does 113 Studies of NAD+ Actually Show?

That absence is the headline finding, not a footnote: the specific administration route most widely marketed to consumers — IV or intramuscular NAD+ — is the one route the literature has not yet tested for the outcomes it is sold on. This is a literature synthesis, not a new trial, and it echoes the same evidence-gap pattern this week's sports-medicine review found for BPC-157 and TB-500.

Are GLP-1 Drugs Safe for People With Opioid Use Disorder?

This is a safety study of licensed pharmaceutical GLP-1 drugs, not an efficacy trial and not about retatrutide specifically — but it is the one item this week that reads as good news rather than a gap between hype and evidence. Target trial emulation using real-world claims data cannot rule out unmeasured confounding the way a randomised trial can, though the consistency across ten separate outcomes is a reasonably strong signal.

How Do This Week's Stories Connect?

The exception proves the pattern rather than breaking it: this week's one reassuring result — GLP-1 drugs showing no elevated risk in opioid use disorder — is also the one study about a fully licensed pharmaceutical class with a decade of real-world claims data behind it, not an investigational or compounded peptide. Evidence quality tracks regulatory maturity closely across all five stories.

What Happens Next?

What Should UK and Irish Researchers Take From This Week?

None of this week's five stories changes the regulatory status of research peptides in the UK or Ireland. The gray-market outcomes study concerns unlicensed sellers supplying product for human injection; the sports-medicine and NAD+ reviews are literature audits of existing published evidence; the MOTS-c paper is animal mechanism data plus a non-interventional human arm; and the GLP-1 safety study concerns licensed pharmaceuticals. See our guide on whether research peptides are legal in the UK for the fuller regulatory picture.

Retatrutide is supplied as a research reagent only. It is not a medicine and has not been evaluated by the MHRA, HPRA or FDA. Not for human or veterinary consumption. See our Research Use Policy and MHRA Statement.

Frequently Asked Questions